Publication: Diabetes y cáncer
Loading...
Official URL
Full text at PDC
Publication Date
2017
Authors
Advisors (or tutors)
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
Citations
Exportar
Abstract
Evidencias epidemiológicas cada vez mayores sugieren una asociación positiva entre la diabetes mellitus tipo 2 (DM2) y el cáncer, dos enfermedades con gran impacto a nivel global. Estos estudios que ponen de manifiesto el mayor riesgo de algunos tipos de cáncer y de mortalidad relacionada con el cáncer que padecen los pacientes con DM2, atribuyen dicha circunstancia a la hiperinsulinemia, elevados niveles de IGF, insulinorresistencia, adipocitoquinas, la aumentada biodisponibilidad de las hormonas sexuales y ambiente proinflamatorio. Asimismo, señalan la influencia de los tratamientos antidiabéticos en el desarrollo y pronóstico del cáncer, y el hecho de que la metformina muestre razonablemente disminuir el riesgo de cáncer en estos pacientes apoya dicha asociación. En base a esto, están siendo desarrolladas nuevas terapias antineoplásicas apuntando a la insulina e IGF como diana.
Growing epidemiological evidences suggest a positive association between type 2 diabetes mellitus (DM2) and cancer, both two diseases with tremendous impact on health worldwide. Studies showing the increased risk of some types of cancer and cancer-related mortality among patients with DM2 attribute this situation to hyperinsulinemia, elevated levels of IGF, insulin resistance, adipocytokines, increased bioavailability of sex hormones and proinflammatory environment. Additionally, they note the influence of antidiabetic treatments in cancer development and prognosis, and the fact that the metformin may decrease the risk of cancer among these patients supports this association. Therefore, new therapies targeting insulin and IGF are being developed for use in cancer therapy.
Growing epidemiological evidences suggest a positive association between type 2 diabetes mellitus (DM2) and cancer, both two diseases with tremendous impact on health worldwide. Studies showing the increased risk of some types of cancer and cancer-related mortality among patients with DM2 attribute this situation to hyperinsulinemia, elevated levels of IGF, insulin resistance, adipocytokines, increased bioavailability of sex hormones and proinflammatory environment. Additionally, they note the influence of antidiabetic treatments in cancer development and prognosis, and the fact that the metformin may decrease the risk of cancer among these patients supports this association. Therefore, new therapies targeting insulin and IGF are being developed for use in cancer therapy.